Neeraj Agarwal, MD, Huntsman Cancer Institute

Articles by Neeraj Agarwal, MD, Huntsman Cancer Institute

Future of Treating mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Treating Patients With mRCC Beyond Second-Line

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Choosing Second-Line Therapy in Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Tailored Therapy Approaches for Upfront mRCC Treatment

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Treating Side Effects of Therapy for mRCC with Steroids

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluating Safety Profiles of Upfront Regimens for mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Choosing Upfront Therapy for mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Patient Factor Consideration for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Applying Clinical Trial Data for Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

ByDaniel J. George, MD, Duke Cancer Center,Neeraj Agarwal, MD, Huntsman Cancer Institute,Rana R. McKay, MD, University of California San Diego Medical Center,Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

July 23rd 2020

Latest Updated Articles

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC
July 23rd 2020
$Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC$
Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC
July 23rd 2020
Tailored Therapy Approaches for Upfront mRCC Treatment
July 23rd 2020
Patient Factor Consideration for Treatment of mRCC
July 23rd 2020
Future of Treating mRCC
July 23rd 2020
Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC
July 23rd 2020

Trending on OncLive

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC

Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL